Purpose: The pathogenesis of osteoarthritis (OA) is believed to involve the actions of pro-inflammatory cytokines such as interleukin 1 (IL-1). However, there are currently no disease-modifying OA drugs (DMOADs) available to combat joint degeneration. A major limitation to developing OA therapeutics is the availability of a high-throughput, patient-specific screening system. Induced pluripotent stem cells (iPSCs) provide an attractive cell source for this type of system, as they can be derived from a skin biopsy and can be expanded indefinitely in culture. Recent work in our lab has demonstrated that cartilage engineered from iPSCs can recapitulate many of the properties of native tissue. This approach can provide virtually unlimited quantities of genetically defined cartilage as a model system of OA, facilitating the development of high-throughput screening assays for DMOADs. The goal of this study was to examine the influence of IL-1α on iPSC-derived cartilage as an in vitro model of OA for drug screening. Methods: A multistep differentiation and purification protocol was used to derive high quality engineered cartilage from murine iPSCs derived from tail fibroblasts. Cells were first differentiated in micromasses using BMP-4 and then purified based on the collagen II promoter/enhancer driving GFP expression. Purified cells were expanded and then cultured as pellets for 3 wks in chondrogenic media containing dexamethasone and TGF-β3, producing a robust cartilaginous matrix. As a model of OA, pellets were cultured in standard media with IL-1α (0, 10, or 100 pg/ml, or 1 ng/ml). After 3 days of culture, the elastic modulus of the pellets was measured using atomic force microscopy, and the DNA, glycosaminoglycan (GAG), and collagen contents of the pellets were analyzed biochemically and histologically. Additionally, the media were collected and analyzed for matrix metalloproteinase (MMP) activity and GAG, nitric oxide (NO), and prostaglandin E2 (PGE2). Results: Treatment of iPSC neocartilage with IL-1α produced a clear degenerative response. MMP release was significantly increased in all treatment groups from a 27-fold increase at 10 pg to a 340-fold increase at 1 ng/ml (Fig. 1A). The increase in MMPs was associated with a significant loss of GAGs from the pellet into the media. IL-1α at a dose of 1 ng/ml increased the percentage of total GAG in the media from 19% to 61% (Fig. 1B). Similar trends were apparent for the production of NO and PGE2, with >6-fold increases at 1 ng/ml IL-1α. Histological analysis confirmed matrix degradation, with a dramatic decrease in sulfated GAG staining in the high treatment groups (Fig. 2A). IL-1α treatment at 1 ng/ml also resulted in a 68% decrease in the compressive modulus (Fig. 2B). Conclusions: iPSC-derived cartilage displayed a dramatic and dose-dependent catabolic response to IL-1α, similar to that of native cartilage. The observed matrix degradation, loss of mechanical properties, and production of inflammatory mediators were all consistent with an OA phenotype. This system also showed the ability to be tailored, as dose dependent responses of the pellets to IL-1α may be useful for modeling different stages of the disease or different joint space environments. This work provides an initial demonstration of the potential of iPSCs for creating patient-specific in vitro models of arthritis, which may facilitate the discovery of tailored OA therapeutics.Figure 2IL-1α induced degeneration of iPSC neocartilage. (A) Safranin-0 staining confirmed GAG loss from iPSC pellets at high IL-1α doses (positive staining is red, scale bar = 100 μm). (B) The compressive stiffness of iPSC-derived cartilage significantly decreased following IL-1α treatments above 100 pg/ml. Groups not connected by the same letter as statistically different with P < 0.05. Mean ±SEM.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
Read full abstract